StockMirror — Stock Screener

WINDLAS Q4 FY26 Results & Earnings Analysis

Sentiment: Good (Confidence: medium)

Earnings Summary

Windlas Biotech delivered a strong FY26, with 19% revenue growth to INR904cr, driven by the CDMO and Export verticals. While profitability margins (reported) remained flat, operational efficiency improved. The company faces a near-term headwind in the Trade Generics vertical from the codeine product ban, but management is working to replenish this through new products. The long-term outlook remains positive, anchored by a growing CDMO business, new injectable capacity, and expanding exports. Financial discipline, particularly in working capital and capital allocation, remains a core strength. , , ,

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasizes a balanced approach, aiming for growth across three verticals while maintaining financial discipline, capital efficiency (25%+ ROCE/ROE), and improving operational EBITDA margins. ,

About Windlas Biotech Limited

Windlas Biotech Limited (WINDLAS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More